{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:35:32Z","timestamp":1793396132869,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2024J345"],"award-info":[{"award-number":["2024J345"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2024J037"],"award-info":[{"award-number":["2024J037"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270821"],"award-info":[{"award-number":["32270821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Youth Science and Technology Innovation Leader of Ningbo","award":["2023QL052"],"award-info":[{"award-number":["2023QL052"]}]},{"DOI":"10.13039\/501100010229","name":"Natural Science Foundation of Tianjin Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["LY24C050001"],"award-info":[{"award-number":["LY24C050001"]}],"id":[{"id":"10.13039\/501100010229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06271-2","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:54:51Z","timestamp":1741269291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The impact of dysregulation SUMOylation on prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-4742","authenticated-orcid":false,"given":"Kailang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bitao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"6271_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"6271_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268\u201378. https:\/\/doi.org\/10.1038\/nrc2351.","journal-title":"Nat Rev Cancer"},{"key":"6271_CR3","doi-asserted-by":"publisher","first-page":"100962","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother. 2023;68:100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962.","journal-title":"Drug Resist Updates: Reviews Commentaries Antimicrob Anticancer Chemother"},{"key":"6271_CR4","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate Cancer. Endocr Rev. 2021;42:354\u201373. https:\/\/doi.org\/10.1210\/endrev\/bnab002.","journal-title":"Endocr Rev"},{"key":"6271_CR5","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, et al. Enzalutamide in men with nonmetastatic, Castration-Resistant prostate Cancer. N Engl J Med. 2018;378:2465\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1800536.","journal-title":"N Engl J Med"},{"key":"6271_CR6","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360. https:\/\/doi.org\/10.1016\/s1470-2045(14)71205-7.","journal-title":"Lancet Oncol"},{"key":"6271_CR7","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc.2016.143","volume":"17","author":"JS Seeler","year":"2017","unstructured":"Seeler JS, Dejean A. SUMO and the robustness of cancer. Nat Rev Cancer. 2017;17:184\u201397. https:\/\/doi.org\/10.1038\/nrc.2016.143.","journal-title":"Nat Rev Cancer"},{"key":"6271_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41580-022-00500-y","volume":"23","author":"ACO Vertegaal","year":"2022","unstructured":"Vertegaal ACO. Signalling mechanisms and cellular functions of SUMO. Nat Rev Mol Cell Biol. 2022;23:715\u201331. https:\/\/doi.org\/10.1038\/s41580-022-00500-y.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6271_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.semcdb.2021.11.007","volume":"132","author":"J Lascorz","year":"2022","unstructured":"Lascorz J, Codina-Fabra J, Reverter D, Torres-Rosell J. SUMO-SIM interactions: from structure to biological functions. Semin Cell Dev Biol. 2022;132:193\u2013202. https:\/\/doi.org\/10.1016\/j.semcdb.2021.11.007.","journal-title":"Semin Cell Dev Biol"},{"key":"6271_CR10","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1152\/physrev.00025.2019","volume":"100","author":"HM Chang","year":"2020","unstructured":"Chang HM, Yeh ETH. SUMO: from bench to bedside. Physiol Rev. 2020;100:1599\u2013619. https:\/\/doi.org\/10.1152\/physrev.00025.2019.","journal-title":"Physiol Rev"},{"key":"6271_CR11","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nrm3011","volume":"11","author":"JR Gareau","year":"2010","unstructured":"Gareau JR, Lima CD. The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol. 2010;11:861\u201371. https:\/\/doi.org\/10.1038\/nrm3011.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6271_CR12","doi-asserted-by":"publisher","first-page":"35368","DOI":"10.1074\/jbc.M104214200","volume":"276","author":"MH Tatham","year":"2001","unstructured":"Tatham MH, et al. Polymeric chains of SUMO-2 and SUMO-3 are conjugated to protein substrates by SAE1\/SAE2 and Ubc9 *. J Biol Chem. 2001;276:35368\u201374. https:\/\/doi.org\/10.1074\/jbc.M104214200.","journal-title":"J Biol Chem"},{"key":"6271_CR13","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1091\/mbc.E21-01-0031","volume":"32","author":"D Bouchard","year":"2021","unstructured":"Bouchard D, et al. SUMO paralogue-specific functions revealed through systematic analysis of human knockout cell lines and gene expression data. Mol Biol Cell. 2021;32:1849\u201366. https:\/\/doi.org\/10.1091\/mbc.E21-01-0031.","journal-title":"Mol Biol Cell"},{"key":"6271_CR14","doi-asserted-by":"publisher","unstructured":"Lumahan LEV, Arif M, Whitener AE, Yi P. Regulating androgen receptor function in prostate cancer: exploring the diversity of Post-Translational modifications. Cells. 2024; 13. https:\/\/doi.org\/10.3390\/cells13020191.","DOI":"10.3390\/cells13020191"},{"key":"6271_CR15","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.humpath.2010.02.007","volume":"41","author":"SJ Moschos","year":"2010","unstructured":"Moschos SJ, et al. Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues. Hum Pathol. 2010;41:1286\u201398. https:\/\/doi.org\/10.1016\/j.humpath.2010.02.007.","journal-title":"Hum Pathol"},{"key":"6271_CR16","doi-asserted-by":"publisher","first-page":"14145","DOI":"10.1073\/pnas.97.26.14145","volume":"97","author":"H Poukka","year":"2000","unstructured":"Poukka H, Karvonen U, Janne OA, Palvimo JJ. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc Natl Acad Sci U S A. 2000;97:14145\u201350. https:\/\/doi.org\/10.1073\/pnas.97.26.14145.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6271_CR17","doi-asserted-by":"publisher","first-page":"19441","DOI":"10.1074\/jbc.274.27.19441","volume":"274","author":"H Poukka","year":"1999","unstructured":"Poukka H, Aarnisalo P, Karvonen U, Palvimo JJ, J\u00e4nne OA. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription. J Biol Chem. 1999;274:19441\u20136. https:\/\/doi.org\/10.1074\/jbc.274.27.19441.","journal-title":"J Biol Chem"},{"key":"6271_CR18","doi-asserted-by":"publisher","unstructured":"Xiao J, et al. UBC9 deficiency enhances immunostimulatory macrophage activation and subsequent antitumor T cell response in prostate cancer. J Clin Invest. 2023; 133. https:\/\/doi.org\/10.1172\/jci158352.","DOI":"10.1172\/jci158352"},{"key":"6271_CR19","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1038\/s41388-018-0641-1","volume":"38","author":"D Jang","year":"2019","unstructured":"Jang D, Kwon H, Choi M, Lee J, Pak Y. Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing snail degradation. Oncogene. 2019;38:3248\u201360. https:\/\/doi.org\/10.1038\/s41388-018-0641-1.","journal-title":"Oncogene"},{"key":"6271_CR20","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1016\/j.febslet.2015.11.028","volume":"589","author":"HJ Choi","year":"2015","unstructured":"Choi HJ, Park JH, Park JH, Lee KB, Oh SM. Pc2-mediated sumoylation of WWOX is essential for its suppression of DU145 prostate tumorigenesis. FEBS Lett. 2015;589:3977\u201388. https:\/\/doi.org\/10.1016\/j.febslet.2015.11.028.","journal-title":"FEBS Lett"},{"key":"6271_CR21","doi-asserted-by":"publisher","first-page":"20793","DOI":"10.1073\/pnas.0710343105","volume":"104","author":"JH Kim","year":"2007","unstructured":"Kim JH, et al. SUMOylation of Pontin chromatin-remodeling complex reveals a signal integration code in prostate cancer cells. Proc Natl Acad Sci U S A. 2007;104:20793\u20138. https:\/\/doi.org\/10.1073\/pnas.0710343105.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6271_CR22","doi-asserted-by":"publisher","first-page":"5357","DOI":"10.1038\/s41388-021-01937-9","volume":"40","author":"L Mei","year":"2021","unstructured":"Mei L, et al. SUMOylation activates large tumour suppressor 1 to maintain the tissue homeostasis during Hippo signalling. Oncogene. 2021;40:5357\u201366. https:\/\/doi.org\/10.1038\/s41388-021-01937-9.","journal-title":"Oncogene"},{"key":"6271_CR23","doi-asserted-by":"publisher","first-page":"e48019","DOI":"10.1371\/journal.pone.0048019","volume":"7","author":"NS Belaguli","year":"2012","unstructured":"Belaguli NS, Zhang M, Brunicardi FC, Berger DH. Forkhead box protein A2 (FOXA2) protein stability and activity are regulated by sumoylation. PLoS ONE. 2012;7:e48019. https:\/\/doi.org\/10.1371\/journal.pone.0048019.","journal-title":"PLoS ONE"},{"key":"6271_CR24","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00018-009-0061-z","volume":"66","author":"MM Rytinki","year":"2009","unstructured":"Rytinki MM, Kaikkonen S, Pehkonen P, J\u00e4\u00e4skel\u00e4inen T, Palvimo JJ. PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci. 2009;66:3029\u201341. https:\/\/doi.org\/10.1007\/s00018-009-0061-z.","journal-title":"Cell Mol Life Sci"},{"key":"6271_CR25","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.ajpath.2012.01.026","volume":"180","author":"J Hoefer","year":"2012","unstructured":"Hoefer J, et al. PIAS1 is increased in human prostate cancer and enhances proliferation through Inhibition of p21. Am J Pathol. 2012;180:2097\u2013107. https:\/\/doi.org\/10.1016\/j.ajpath.2012.01.026.","journal-title":"Am J Pathol"},{"key":"6271_CR26","doi-asserted-by":"publisher","first-page":"12043","DOI":"10.18632\/oncotarget.2658","volume":"5","author":"M Puhr","year":"2014","unstructured":"Puhr M, et al. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells. Oncotarget. 2014;5:12043\u201356. https:\/\/doi.org\/10.18632\/oncotarget.2658.","journal-title":"Oncotarget"},{"key":"6271_CR27","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1093\/nar\/gku1375","volume":"43","author":"S Toropainen","year":"2015","unstructured":"Toropainen S, et al. SUMO ligase PIAS1 functions as a target gene selective androgen receptor coregulator on prostate cancer cell chromatin. Nucleic Acids Res. 2015;43:848\u201361. https:\/\/doi.org\/10.1093\/nar\/gku1375.","journal-title":"Nucleic Acids Res"},{"key":"6271_CR28","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1038\/onc.2015.292","volume":"35","author":"M Puhr","year":"2016","unstructured":"Puhr M, et al. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer. Oncogene. 2016;35:2322\u201332. https:\/\/doi.org\/10.1038\/onc.2015.292.","journal-title":"Oncogene"},{"key":"6271_CR29","doi-asserted-by":"publisher","first-page":"41311","DOI":"10.1074\/jbc.M206741200","volume":"277","author":"T Nishida","year":"2002","unstructured":"Nishida T, Yasuda H. PIAS1 and PIASxalpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription. J Biol Chem. 2002;277:41311\u20137. https:\/\/doi.org\/10.1074\/jbc.M206741200.","journal-title":"J Biol Chem"},{"key":"6271_CR30","doi-asserted-by":"publisher","first-page":"14833","DOI":"10.3390\/ijms140714833","volume":"14","author":"T van der Steen","year":"2013","unstructured":"van der Steen T, Tindall DJ, Huang H. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 2013;14:14833\u201359. https:\/\/doi.org\/10.3390\/ijms140714833.","journal-title":"Int J Mol Sci"},{"key":"6271_CR31","doi-asserted-by":"publisher","first-page":"5742","DOI":"10.1158\/0008-5472.CAN-13-0538","volume":"73","author":"R Li","year":"2013","unstructured":"Li R, et al. Akt sumoylation regulates cell proliferation and tumorigenesis. Cancer Res. 2013;73:5742\u201353. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-0538.","journal-title":"Cancer Res"},{"key":"6271_CR32","first-page":"1319","volume":"11","author":"L Wang","year":"2004","unstructured":"Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep. 2004;11:1319\u201324.","journal-title":"Oncol Rep"},{"key":"6271_CR33","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.3892\/mmr.2014.1993","volume":"9","author":"Z Zhao","year":"2014","unstructured":"Zhao Z, Wu L, Shi H, Wu C. p53 N\u2013terminal binding and stabilisation by PIAS3 inhibits MDM2\u2013induced p53 ubiquitination and regulates cell growth. Mol Med Rep. 2014;9:1903\u20138. https:\/\/doi.org\/10.3892\/mmr.2014.1993.","journal-title":"Mol Med Rep"},{"key":"6271_CR34","doi-asserted-by":"publisher","first-page":"3880","DOI":"10.1038\/sj.onc.1204489","volume":"20","author":"M Gross","year":"2001","unstructured":"Gross M, et al. Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene. 2001;20:3880\u20137. https:\/\/doi.org\/10.1038\/sj.onc.1204489.","journal-title":"Oncogene"},{"key":"6271_CR35","doi-asserted-by":"publisher","first-page":"17852","DOI":"10.1074\/jbc.M201689200","volume":"277","author":"BA Wible","year":"2002","unstructured":"Wible BA, et al. Increased K\u2009+\u2009efflux and apoptosis induced by the potassium channel modulatory protein KChAP\/PIAS3beta in prostate cancer cells. J Biol Chem. 2002;277:17852\u201362. https:\/\/doi.org\/10.1074\/jbc.M201689200.","journal-title":"J Biol Chem"},{"key":"6271_CR36","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1074\/jbc.M113.508515","volume":"289","author":"W Wang","year":"2014","unstructured":"Wang W, et al. PIASx\u03b1 ligase enhances SUMO1 modification of PTEN protein as a SUMO E3 ligase. J Biol Chem. 2014;289:3217\u201330. https:\/\/doi.org\/10.1074\/jbc.M113.508515.","journal-title":"J Biol Chem"},{"key":"6271_CR37","doi-asserted-by":"publisher","first-page":"4523","DOI":"10.1093\/nar\/gkm476","volume":"35","author":"J Lee","year":"2007","unstructured":"Lee J, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor. Nucleic Acids Res. 2007;35:4523\u201334. https:\/\/doi.org\/10.1093\/nar\/gkm476.","journal-title":"Nucleic Acids Res"},{"key":"6271_CR38","doi-asserted-by":"publisher","first-page":"23748","DOI":"10.1074\/jbc.M508365200","volume":"281","author":"X Li","year":"2006","unstructured":"Li X, Thyssen G, Beliakoff J, Sun Z. The novel PIAS-like protein hZimp10 enhances Smad transcriptional activity. J Biol Chem. 2006;281:23748\u201356. https:\/\/doi.org\/10.1074\/jbc.M508365200.","journal-title":"J Biol Chem"},{"key":"6271_CR39","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1093\/emboj\/cdg585","volume":"22","author":"M Sharma","year":"2003","unstructured":"Sharma M, et al. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. Embo J. 2003;22:6101\u201314. https:\/\/doi.org\/10.1093\/emboj\/cdg585.","journal-title":"Embo J"},{"key":"6271_CR40","doi-asserted-by":"publisher","first-page":"153303382311786","DOI":"10.1177\/15330338231178639","volume":"22","author":"Y Pan","year":"2023","unstructured":"Pan Y, Yu H, Lu F. TRIM11 posttranscriptionally modulated by miR-5193 facilitates tumor growth and metastasis of prostate Cancer. Technol Cancer Res Treat. 2023;22:15330338231178639. https:\/\/doi.org\/10.1177\/15330338231178639.","journal-title":"Technol Cancer Res Treat"},{"key":"6271_CR41","first-page":"1868","volume":"57","author":"D He","year":"1997","unstructured":"He D, et al. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells. Cancer Res. 1997;57:1868\u201372.","journal-title":"Cancer Res"},{"key":"6271_CR42","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.gendis.2020.07.003","volume":"8","author":"J Liu","year":"2021","unstructured":"Liu J, Zhang C, Wang X, Hu W, Feng Z. Tumor suppressor p53 cross-talks with TRIM family proteins. Genes Dis. 2021;8:463\u201374. https:\/\/doi.org\/10.1016\/j.gendis.2020.07.003.","journal-title":"Genes Dis"},{"key":"6271_CR43","doi-asserted-by":"publisher","first-page":"109686","DOI":"10.1016\/j.cellsig.2020.109686","volume":"73","author":"S Li","year":"2020","unstructured":"Li S, et al. SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway. Cell Signal. 2020;73:109686. https:\/\/doi.org\/10.1016\/j.cellsig.2020.109686.","journal-title":"Cell Signal"},{"key":"6271_CR44","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41388-017-0095-x","volume":"37","author":"KI Takayama","year":"2018","unstructured":"Takayama KI, et al. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer. Oncogene. 2018;37:2165\u201380. https:\/\/doi.org\/10.1038\/s41388-017-0095-x.","journal-title":"Oncogene"},{"key":"6271_CR45","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jmb.2008.07.016","volume":"382","author":"U Karvonen","year":"2008","unstructured":"Karvonen U, J\u00e4\u00e4skel\u00e4inen T, Rytinki M, Kaikkonen S, Palvimo JJ. ZNF451 is a novel PML body- and SUMO-associated transcriptional coregulator. J Mol Biol. 2008;382:585\u2013600. https:\/\/doi.org\/10.1016\/j.jmb.2008.07.016.","journal-title":"J Mol Biol"},{"key":"6271_CR46","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1038\/onc.2012.250","volume":"32","author":"Q Wang","year":"2013","unstructured":"Wang Q, et al. SUMO-specific protease 1 promotes prostate cancer progression and metastasis. Oncogene. 2013;32:2493\u20138. https:\/\/doi.org\/10.1038\/onc.2012.250.","journal-title":"Oncogene"},{"key":"6271_CR47","doi-asserted-by":"publisher","unstructured":"Shao Z, et al. SENP3 mediates desumoylation of SIX1 to promote prostate cancer proliferation and migration. Cell Mol Biol Lett. 2024; 29. https:\/\/doi.org\/10.1186\/s11658-024-00665-8.","DOI":"10.1186\/s11658-024-00665-8"},{"key":"6271_CR48","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1593\/neo.06445","volume":"8","author":"J Cheng","year":"2006","unstructured":"Cheng J, Bawa T, Lee P, Gong L, Yeh ET. Role of desumoylation in the development of prostate cancer. Neoplasia (New York N Y). 2006;8:667\u201376. https:\/\/doi.org\/10.1593\/neo.06445.","journal-title":"Neoplasia (New York N Y)"},{"key":"6271_CR49","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1159\/000489370","volume":"46","author":"HR Luo","year":"2018","unstructured":"Luo HR, et al. Sumoylation negatively regulates CSR1-Dependent prostate Cancer cell death. Cell Physiol Biochemistry: Int J Experimental Cell Physiol Biochem Pharmacol. 2018;46:1861\u20137. https:\/\/doi.org\/10.1159\/000489370.","journal-title":"Cell Physiol Biochemistry: Int J Experimental Cell Physiol Biochem Pharmacol"},{"key":"6271_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.21037\/tau-21-1110","volume":"11","author":"L Hao","year":"2022","unstructured":"Hao L, et al. Melatonin decreases androgen-sensitive prostate cancer growth by suppressing SENP1 expression. Translational Androl Urol. 2022;11:91\u2013103. https:\/\/doi.org\/10.21037\/tau-21-1110.","journal-title":"Translational Androl Urol"},{"key":"6271_CR51","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/s41467-021-22163-7","volume":"12","author":"X Shangguan","year":"2021","unstructured":"Shangguan X, et al. SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis. Nat Commun. 2021;12:1812. https:\/\/doi.org\/10.1038\/s41467-021-22163-7.","journal-title":"Nat Commun"},{"key":"6271_CR52","doi-asserted-by":"publisher","first-page":"17651","DOI":"10.18632\/oncotarget.13283","volume":"8","author":"T Bawa-Khalfe","year":"2017","unstructured":"Bawa-Khalfe T, et al. SENP1 regulates PTEN stability to dictate prostate cancer development. Oncotarget. 2017;8:17651\u201364. https:\/\/doi.org\/10.18632\/oncotarget.13283.","journal-title":"Oncotarget"},{"key":"6271_CR53","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.celrep.2015.09.083","volume":"13","author":"H Zhu","year":"2015","unstructured":"Zhu H, et al. SPOP E3 ubiquitin ligase adaptor promotes cellular senescence by degrading the SENP7 desumoylase. Cell Rep. 2015;13:1183\u201393. https:\/\/doi.org\/10.1016\/j.celrep.2015.09.083.","journal-title":"Cell Rep"},{"key":"6271_CR54","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nsmb.3366","volume":"24","author":"IA Hendriks","year":"2017","unstructured":"Hendriks IA, et al. Site-specific mapping of the human SUMO proteome reveals co-modification with phosphorylation. Nat Struct Mol Biol. 2017;24:325\u201336. https:\/\/doi.org\/10.1038\/nsmb.3366.","journal-title":"Nat Struct Mol Biol"},{"key":"6271_CR55","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.7150\/thno.54967","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Chen Y, Jin M, Wang J. The crosstalk between m(6)A RNA methylation and other epigenetic regulators: a novel perspective in epigenetic remodeling. Theranostics. 2021;11:4549\u201366. https:\/\/doi.org\/10.7150\/thno.54967.","journal-title":"Theranostics"},{"key":"6271_CR56","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1038\/onc.2010.600","volume":"30","author":"Y Yang","year":"2011","unstructured":"Yang Y, et al. Inhibition of androgen receptor activity by histone deacetylase 4 through receptor sumoylation. Oncogene. 2011;30:2207\u201318. https:\/\/doi.org\/10.1038\/onc.2010.600.","journal-title":"Oncogene"},{"key":"6271_CR57","doi-asserted-by":"publisher","first-page":"31195","DOI":"10.1074\/jbc.M112.395210","volume":"287","author":"S Mukherjee","year":"2012","unstructured":"Mukherjee S, Cruz-Rodr\u00edguez O, Bolton E, I\u00f1iguez-Lluh\u00ed JA. The in vivo role of androgen receptor sumoylation as revealed by androgen insensitivity syndrome and prostate cancer mutations targeting the Proline\/glycine residues of synergy control motifs. J Biol Chem. 2012;287:31195\u2013206. https:\/\/doi.org\/10.1074\/jbc.M112.395210.","journal-title":"J Biol Chem"},{"key":"6271_CR58","doi-asserted-by":"publisher","unstructured":"Yang N, et al. SUMO3 modification by PIAS1 modulates androgen receptor cellular distribution and stability. Cell Commun Signal. 2019; 17. https:\/\/doi.org\/10.1186\/s12964-019-0457-9.","DOI":"10.1186\/s12964-019-0457-9"},{"key":"6271_CR59","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1128\/mcb.00753-12","volume":"32","author":"M Rytinki","year":"2012","unstructured":"Rytinki M, et al. Dynamic sumoylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol Cell Biol. 2012;32:4195\u2013205. https:\/\/doi.org\/10.1128\/mcb.00753-12.","journal-title":"Mol Cell Biol"},{"key":"6271_CR60","doi-asserted-by":"publisher","first-page":"4002","DOI":"10.1074\/jbc.M509260200","volume":"281","author":"Z Zheng","year":"2006","unstructured":"Zheng Z, et al. SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells. J Biol Chem. 2006;281:4002\u201312. https:\/\/doi.org\/10.1074\/jbc.M509260200.","journal-title":"J Biol Chem"},{"key":"6271_CR61","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1093\/nar\/gkae653","volume":"52","author":"KM Launonen","year":"2024","unstructured":"Launonen KM, et al. Central role of sumoylation in the regulation of chromatin interactions and transcriptional outputs of the androgen receptor in prostate cancer cells. Nucleic Acids Res. 2024;52:9519\u201335. https:\/\/doi.org\/10.1093\/nar\/gkae653.","journal-title":"Nucleic Acids Res"},{"key":"6271_CR62","doi-asserted-by":"publisher","first-page":"116338","DOI":"10.1016\/j.biopha.2024.116338","volume":"173","author":"X Li","year":"2024","unstructured":"Li X, et al. Androgen receptor cofactors: A potential role in Understanding prostate cancer. Biomed pharmacotherapy = Biomedecine Pharmacotherapie. 2024;173:116338. https:\/\/doi.org\/10.1016\/j.biopha.2024.116338.","journal-title":"Biomed pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"6271_CR63","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1128\/mcb.24.24.10529-10541.2004","volume":"24","author":"DY Lin","year":"2004","unstructured":"Lin DY, et al. Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol. 2004;24:10529\u201341. https:\/\/doi.org\/10.1128\/mcb.24.24.10529-10541.2004.","journal-title":"Mol Cell Biol"},{"key":"6271_CR64","doi-asserted-by":"publisher","first-page":"23658","DOI":"10.1074\/jbc.M203690200","volume":"277","author":"G David","year":"2002","unstructured":"David G, Neptune MA, DePinho RA. SUMO-1 modification of histone deacetylase 1 (HDAC1) modulates its biological activities. J Biol Chem. 2002;277:23658\u201363. https:\/\/doi.org\/10.1074\/jbc.M203690200.","journal-title":"J Biol Chem"},{"key":"6271_CR65","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1128\/mcb.24.13.6021-6028.2004","volume":"24","author":"J Cheng","year":"2004","unstructured":"Cheng J, Wang D, Wang Z, Yeh ET. SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1. Mol Cell Biol. 2004;24:6021\u20138. https:\/\/doi.org\/10.1128\/mcb.24.13.6021-6028.2004.","journal-title":"Mol Cell Biol"},{"key":"6271_CR66","doi-asserted-by":"publisher","first-page":"7938","DOI":"10.1158\/0008-5472.Can-08-0932","volume":"68","author":"EL Clark","year":"2008","unstructured":"Clark EL, et al. The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res. 2008;68:7938\u201346. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-0932.","journal-title":"Cancer Res"},{"key":"6271_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/bi901263m","volume":"49","author":"SM Mooney","year":"2010","unstructured":"Mooney SM, Grande JP, Salisbury JL, Janknecht R. Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential. Biochemistry. 2010;49:1\u201310. https:\/\/doi.org\/10.1021\/bi901263m.","journal-title":"Biochemistry"},{"key":"6271_CR68","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.1038\/sj.onc.1210387","volume":"26","author":"AM Jacobs","year":"2007","unstructured":"Jacobs AM, et al. SUMO modification of the DEAD box protein p68 modulates its transcriptional activity and promotes its interaction with HDAC1. Oncogene. 2007;26:5866\u201376. https:\/\/doi.org\/10.1038\/sj.onc.1210387.","journal-title":"Oncogene"},{"key":"6271_CR69","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1210\/me.2008-0219","volume":"23","author":"S Kaikkonen","year":"2009","unstructured":"Kaikkonen S, et al. SUMO-specific protease 1 (SENP1) reverses the hormone-augmented sumoylation of androgen receptor and modulates gene responses in prostate cancer cells. Mol Endocrinol. 2009;23:292\u2013307. https:\/\/doi.org\/10.1210\/me.2008-0219.","journal-title":"Mol Endocrinol"},{"key":"6271_CR70","doi-asserted-by":"publisher","first-page":"37341","DOI":"10.1074\/jbc.M706978200","volume":"282","author":"T Bawa-Khalfe","year":"2007","unstructured":"Bawa-Khalfe T, Cheng J, Wang Z, Yeh ET. Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells. J Biol Chem. 2007;282:37341\u20139. https:\/\/doi.org\/10.1074\/jbc.M706978200.","journal-title":"J Biol Chem"},{"key":"6271_CR71","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.toxlet.2014.07.003","volume":"229","author":"R Wu","year":"2014","unstructured":"Wu R, et al. SUMO-specific protease 1 modulates cadmium-augmented transcriptional activity of androgen receptor (AR) by reversing AR sumoylation. Toxicol Lett. 2014;229:405\u201313. https:\/\/doi.org\/10.1016\/j.toxlet.2014.07.003.","journal-title":"Toxicol Lett"},{"key":"6271_CR72","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-319-95693-0_6","volume":"1095","author":"V Odero-Marah","year":"2018","unstructured":"Odero-Marah V, Hawsawi O, Henderson V, Sweeney J. Epithelial-Mesenchymal transition (EMT) and prostate Cancer. Adv Exp Med Biol. 2018;1095:101\u201310. https:\/\/doi.org\/10.1007\/978-3-319-95693-0_6.","journal-title":"Adv Exp Med Biol"},{"key":"6271_CR73","doi-asserted-by":"publisher","first-page":"97703","DOI":"10.18632\/oncotarget.20097","volume":"8","author":"SK Gudey","year":"2017","unstructured":"Gudey SK, Sundar R, Heldin CH, Bergh A, Landstr\u00f6m M. Pro-invasive properties of Snail1 are regulated by sumoylation in response to TGF\u03b2 stimulation in cancer. Oncotarget. 2017;8:97703\u201326. https:\/\/doi.org\/10.18632\/oncotarget.20097.","journal-title":"Oncotarget"},{"key":"6271_CR74","first-page":"1613","volume":"62","author":"KM Hajra","year":"2002","unstructured":"Hajra KM, Chen DY, Fearon ER. The SLUG zinc-finger protein represses E-cadherin in breast cancer. Cancer Res. 2002;62:1613\u20138.","journal-title":"Cancer Res"},{"key":"6271_CR75","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1016\/j.molonc.2014.05.006","volume":"8","author":"Y Xie","year":"2014","unstructured":"Xie Y, et al. Slug regulates E-cadherin repression via p19Arf in prostate tumorigenesis. Mol Oncol. 2014;8:1355\u201364. https:\/\/doi.org\/10.1016\/j.molonc.2014.05.006.","journal-title":"Mol Oncol"},{"key":"6271_CR76","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.canlet.2018.02.007","volume":"425","author":"W Lin","year":"2018","unstructured":"Lin W, et al. ASC-J9(\u00ae) suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3. Cancer Lett. 2018;425:21\u201330. https:\/\/doi.org\/10.1016\/j.canlet.2018.02.007.","journal-title":"Cancer Lett"},{"key":"6271_CR77","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/nrm3753","volume":"15","author":"NT Snider","year":"2014","unstructured":"Snider NT, Omary MB. Post-translational modifications of intermediate filament proteins: mechanisms and functions. Nat Rev Mol Cell Biol. 2014;15:163\u201377. https:\/\/doi.org\/10.1038\/nrm3753.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"6271_CR78","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41467-020-14581-w","volume":"11","author":"C Li","year":"2020","unstructured":"Li C, et al. Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility. Nat Commun. 2020;11:834. https:\/\/doi.org\/10.1038\/s41467-020-14581-w.","journal-title":"Nat Commun"},{"key":"6271_CR79","doi-asserted-by":"publisher","unstructured":"Zhang X, et al. SUMO-Specific cysteine protease 1 promotes epithelial mesenchymal transition of prostate Cancer cells via regulating SMAD4 desumoylation. Int J Mol Sci. 2017; 18. https:\/\/doi.org\/10.3390\/ijms18040808.","DOI":"10.3390\/ijms18040808"},{"key":"6271_CR80","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-019-1054-7","volume":"18","author":"Z Zhu","year":"2019","unstructured":"Zhu Z, et al. Circular RNA circNHSL1 promotes gastric cancer progression through the miR-1306-3p\/SIX1\/vimentin axis. Mol Cancer. 2019;18:126. https:\/\/doi.org\/10.1186\/s12943-019-1054-7.","journal-title":"Mol Cancer"},{"key":"6271_CR81","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.Cd-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-1059.","journal-title":"Cancer Discov"},{"key":"6271_CR82","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2741\/4443","volume":"21","author":"H Chen","year":"2016","unstructured":"Chen H, et al. The PI3K\/AKT pathway in the pathogenesis of prostate cancer. Front Bioscience (Landmark edition). 2016;21:1084\u201391. https:\/\/doi.org\/10.2741\/4443.","journal-title":"Front Bioscience (Landmark edition)"},{"key":"6271_CR83","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili T, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018;15:222\u201334. https:\/\/doi.org\/10.1038\/nrurol.2018.9.","journal-title":"Nat Rev Urol"},{"key":"6271_CR84","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1038\/ncomms1919","volume":"3","author":"J Huang","year":"2012","unstructured":"Huang J, et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun. 2012;3:911. https:\/\/doi.org\/10.1038\/ncomms1919.","journal-title":"Nat Commun"},{"key":"6271_CR85","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1126\/science.1236188","volume":"341","author":"C Bassi","year":"2013","unstructured":"Bassi C, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science. 2013;341:395\u20139. https:\/\/doi.org\/10.1126\/science.1236188.","journal-title":"Science"},{"key":"6271_CR86","doi-asserted-by":"publisher","first-page":"113872","DOI":"10.1016\/j.yexcr.2023.113872","volume":"434","author":"D De","year":"2024","unstructured":"De D, Ghosh G, Karmakar P. Sumoylation and phosphorylation of PTEN boosts and curtails autophagy respectively by influencing cell membrane localisation. Exp Cell Res. 2024;434:113872. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113872.","journal-title":"Exp Cell Res"},{"key":"6271_CR87","doi-asserted-by":"publisher","first-page":"174807","DOI":"10.1016\/j.ejphar.2022.174807","volume":"919","author":"S Kumari","year":"2022","unstructured":"Kumari S, et al. Therapeutic potential of p53 reactivation in prostate cancer: strategies and opportunities. Eur J Pharmacol. 2022;919:174807. https:\/\/doi.org\/10.1016\/j.ejphar.2022.174807.","journal-title":"Eur J Pharmacol"},{"key":"6271_CR88","doi-asserted-by":"publisher","first-page":"18739","DOI":"10.1073\/pnas.0604083103","volume":"103","author":"K Nakayama","year":"2006","unstructured":"Nakayama K, et al. A BTB\/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A. 2006;103:18739\u201344. https:\/\/doi.org\/10.1073\/pnas.0604083103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6271_CR89","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bbrc.2022.12.015","volume":"641","author":"D Wen","year":"2023","unstructured":"Wen D, Hu M, Guo W, Wu J, Wu Y. Multi-SUMOylation of NAC1 is essential for the growth of prostate cancer cells. Biochem Biophys Res Commun. 2023;641:148\u201354. https:\/\/doi.org\/10.1016\/j.bbrc.2022.12.015.","journal-title":"Biochem Biophys Res Commun"},{"key":"6271_CR90","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/sj.bjc.6606062","volume":"104","author":"AK Ramsay","year":"2011","unstructured":"Ramsay AK, et al. ERK5 signalling in prostate cancer promotes an invasive phenotype. Br J Cancer. 2011;104:664\u201372. https:\/\/doi.org\/10.1038\/sj.bjc.6606062.","journal-title":"Br J Cancer"},{"key":"6271_CR91","doi-asserted-by":"publisher","unstructured":"Erazo T, Espinosa-Gil S, Di\u00e9guez-Mart\u00ednez N, G\u00f3mez N, Lizcano JM. SUMOylation is required for ERK5 nuclear translocation and ERK5-Mediated Cancer cell proliferation. Int J Mol Sci. 2020; 21. https:\/\/doi.org\/10.3390\/ijms21062203.","DOI":"10.3390\/ijms21062203"},{"key":"6271_CR92","doi-asserted-by":"publisher","first-page":"29795","DOI":"10.1074\/jbc.M802515200","volume":"283","author":"X Huang","year":"2008","unstructured":"Huang X, Li X, Guo B. KLF6 induces apoptosis in prostate cancer cells through up-regulation of ATF3. J Biol Chem. 2008;283:29795\u2013801. https:\/\/doi.org\/10.1074\/jbc.M802515200.","journal-title":"J Biol Chem"},{"key":"6271_CR93","doi-asserted-by":"publisher","first-page":"8367","DOI":"10.3390\/ijms14048367","volume":"14","author":"CM Wang","year":"2013","unstructured":"Wang CM, Yang WH. Loss of sumoylation on ATF3 inhibits proliferation of prostate cancer cells by modulating CCND1\/2 activity. Int J Mol Sci. 2013;14:8367\u201380. https:\/\/doi.org\/10.3390\/ijms14048367.","journal-title":"Int J Mol Sci"},{"key":"6271_CR94","first-page":"795","volume":"14","author":"S Oh","year":"2021","unstructured":"Oh S, Shin S, Janknecht R. Sumoylation of transcription factor ETV1 modulates its oncogenic potential in prostate cancer. Int J Clin Exp Pathol. 2021;14:795\u2013810.","journal-title":"Int J Clin Exp Pathol"},{"key":"6271_CR95","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1021\/pr4012848","volume":"13","author":"D Wen","year":"2014","unstructured":"Wen D, et al. Important role of sumoylation of spliceosome factors in prostate cancer cells. J Proteome Res. 2014;13:3571\u201382. https:\/\/doi.org\/10.1021\/pr4012848.","journal-title":"J Proteome Res"},{"key":"6271_CR96","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrc.2016.77","volume":"16","author":"N Hay","year":"2016","unstructured":"Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat Rev Cancer. 2016;16:635\u201349. https:\/\/doi.org\/10.1038\/nrc.2016.77.","journal-title":"Nat Rev Cancer"},{"key":"6271_CR97","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.7150\/thno.97162","volume":"14","author":"H Zhou","year":"2024","unstructured":"Zhou H, et al. Distinctive tumorigenic significance and innovative oncology targets of sumoylation. Theranostics. 2024;14:3127\u201349. https:\/\/doi.org\/10.7150\/thno.97162.","journal-title":"Theranostics"},{"key":"6271_CR98","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ccr.2013.06.014","volume":"24","author":"KC Patra","year":"2013","unstructured":"Patra KC, et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell. 2013;24:213\u201328. https:\/\/doi.org\/10.1016\/j.ccr.2013.06.014.","journal-title":"Cancer Cell"},{"key":"6271_CR99","doi-asserted-by":"publisher","unstructured":"Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther. 2021; 221. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107753.","DOI":"10.1016\/j.pharmthera.2020.107753"},{"key":"6271_CR100","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.trecan.2022.07.002","volume":"8","author":"D Denk","year":"2022","unstructured":"Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends cancer. 2022;8:901\u201314. https:\/\/doi.org\/10.1016\/j.trecan.2022.07.002.","journal-title":"Trends cancer"},{"key":"6271_CR101","doi-asserted-by":"publisher","first-page":"41110","DOI":"10.18632\/oncotarget.9002","volume":"7","author":"SY Park","year":"2016","unstructured":"Park SY, et al. SUMOylation of TBL1 and TBLR1 promotes androgen-independent prostate cancer cell growth. Oncotarget. 2016;7:41110\u201322. https:\/\/doi.org\/10.18632\/oncotarget.9002.","journal-title":"Oncotarget"},{"key":"6271_CR102","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/hep.30917","volume":"71","author":"J Liu","year":"2020","unstructured":"Liu J, et al. Mesencephalic Astrocyte-Derived neurotrophic factor inhibits liver Cancer through small Ubiquitin-Related modifier (SUMO)ylation-Related suppression of NF-\u03baB\/Snail signaling pathway and Epithelial-Mesenchymal transition. Hepatology (Baltimore MD). 2020;71:1262\u201378. https:\/\/doi.org\/10.1002\/hep.30917.","journal-title":"Hepatology (Baltimore MD)"},{"key":"6271_CR103","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/s1097-2765(00)80133-1","volume":"2","author":"JM Desterro","year":"1998","unstructured":"Desterro JM, Rodriguez MS, Hay RT. SUMO-1 modification of IkappaBalpha inhibits NF-kappaB activation. Mol Cell. 1998;2:233\u20139. https:\/\/doi.org\/10.1016\/s1097-2765(00)80133-1.","journal-title":"Mol Cell"},{"key":"6271_CR104","doi-asserted-by":"publisher","first-page":"e51672","DOI":"10.1371\/journal.pone.0051672","volume":"7","author":"F Aillet","year":"2012","unstructured":"Aillet F, et al. Heterologous SUMO-2\/3-ubiquitin chains optimize I\u03baB\u03b1 degradation and NF-\u03baB activity. PLoS ONE. 2012;7:e51672. https:\/\/doi.org\/10.1371\/journal.pone.0051672.","journal-title":"PLoS ONE"},{"key":"6271_CR105","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.it.2019.02.003","volume":"40","author":"P Pathria","year":"2019","unstructured":"Pathria P, Louis TL, Varner JA. Targeting Tumor-Associated macrophages in Cancer. Trends Immunol. 2019;40:310\u201327. https:\/\/doi.org\/10.1016\/j.it.2019.02.003.","journal-title":"Trends Immunol"},{"key":"6271_CR106","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1097\/cco.0000000000000765","volume":"33","author":"L Du","year":"2021","unstructured":"Du L, Liu W, Rosen ST. Targeting sumoylation in cancer. Curr Opin Oncol. 2021;33:520\u20135. https:\/\/doi.org\/10.1097\/cco.0000000000000765.","journal-title":"Curr Opin Oncol"},{"key":"6271_CR107","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13046-023-02813-y","volume":"42","author":"J Zheng","year":"2023","unstructured":"Zheng J, et al. Circ-RAPGEF5 promotes intrahepatic cholangiocarcinoma progression by stabilizing SAE1 to facilitate sumoylation. J Experimental Clin cancer Research: CR. 2023;42:239. https:\/\/doi.org\/10.1186\/s13046-023-02813-y.","journal-title":"J Experimental Clin cancer Research: CR"},{"key":"6271_CR108","doi-asserted-by":"publisher","unstructured":"Shi L, et al. ROS-mediated up-regulation of SAE1 by Helicobacter pylori promotes human gastric tumor genesis and progression. J Translational Med. 2024; 22. https:\/\/doi.org\/10.1186\/s12967-024-04913-5.","DOI":"10.1186\/s12967-024-04913-5"},{"key":"6271_CR109","doi-asserted-by":"publisher","first-page":"8013","DOI":"10.3390\/cimb45100506","volume":"45","author":"YJ Wu","year":"2023","unstructured":"Wu YJ, et al. SUMO-Activating enzyme subunit 1 is associated with poor prognosis, tumor progression, and Radio-Resistance in colorectal Cancer. Curr Issues Mol Biol. 2023;45:8013\u201326. https:\/\/doi.org\/10.3390\/cimb45100506.","journal-title":"Curr Issues Mol Biol"},{"key":"6271_CR110","first-page":"140","volume":"5","author":"DF Shao","year":"2015","unstructured":"Shao DF, et al. High-level SAE2 promotes malignant phenotype and predicts outcome in gastric cancer. Am J cancer Res. 2015;5:140\u201354.","journal-title":"Am J cancer Res"},{"key":"6271_CR111","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/ja.2013.142","volume":"67","author":"M Takemoto","year":"2014","unstructured":"Takemoto M, et al. Inhibition of protein sumoylation by Davidiin, an Ellagitannin from Davidia involucrata. J Antibiot. 2014;67:335\u20138. https:\/\/doi.org\/10.1038\/ja.2013.142.","journal-title":"J Antibiot"},{"key":"6271_CR112","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1021\/ci300618e","volume":"53","author":"A Kumar","year":"2013","unstructured":"Kumar A, Ito A, Hirohama M, Yoshida M, Zhang KY. Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening. J Chem Inf Model. 2013;53:809\u201320. https:\/\/doi.org\/10.1021\/ci300618e.","journal-title":"J Chem Inf Model"},{"key":"6271_CR113","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1038\/s41467-018-07015-1","volume":"9","author":"Z Lv","year":"2018","unstructured":"Lv Z, et al. Molecular mechanism of a covalent allosteric inhibitor of SUMO E1 activating enzyme. Nat Commun. 2018;9:5145. https:\/\/doi.org\/10.1038\/s41467-018-07015-1.","journal-title":"Nat Commun"},{"key":"6271_CR114","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nchembio.2463","volume":"13","author":"X He","year":"2017","unstructured":"He X, et al. Probing the roles of sumoylation in cancer cell biology by using a selective SAE inhibitor. Nat Chem Biol. 2017;13:1164\u201371. https:\/\/doi.org\/10.1038\/nchembio.2463.","journal-title":"Nat Chem Biol"},{"key":"6271_CR115","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1021\/acs.jmedchem.0c01491","volume":"64","author":"SP Langston","year":"2021","unstructured":"Langston SP, et al. Discovery of TAK-981, a First-in-Class inhibitor of SUMO-Activating enzyme for the treatment of Cancer. J Med Chem. 2021;64:2501\u201320. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01491.","journal-title":"J Med Chem"},{"key":"6271_CR116","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1136\/gutjnl-2021-324834","volume":"71","author":"S Kumar","year":"2022","unstructured":"Kumar S, et al. Targeting pancreatic cancer by TAK-981: a sumoylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model. Gut. 2022;71:2266\u201383. https:\/\/doi.org\/10.1136\/gutjnl-2021-324834.","journal-title":"Gut"},{"key":"6271_CR117","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3324\/haematol.2023.282704","volume":"109","author":"L Gabellier","year":"2024","unstructured":"Gabellier L, et al. SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemia. Haematologica. 2024;109:98\u2013114. https:\/\/doi.org\/10.3324\/haematol.2023.282704.","journal-title":"Haematologica"},{"key":"6271_CR118","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13046-021-02226-9","volume":"41","author":"L Du","year":"2022","unstructured":"Du L, et al. SUMOylation Inhibition enhances dexamethasone sensitivity in multiple myeloma. J Experimental Clin cancer Research: CR. 2022;41:8. https:\/\/doi.org\/10.1186\/s13046-021-02226-9.","journal-title":"J Experimental Clin cancer Research: CR"},{"key":"6271_CR119","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41417-022-00450-9","volume":"30","author":"L Du","year":"2023","unstructured":"Du L, Liu W, Pichiorri F, Rosen ST. SUMOylation Inhibition enhances multiple myeloma sensitivity to Lenalidomide. Cancer Gene Ther. 2023;30:567\u201374. https:\/\/doi.org\/10.1038\/s41417-022-00450-9.","journal-title":"Cancer Gene Ther"},{"key":"6271_CR120","doi-asserted-by":"publisher","first-page":"3892","DOI":"10.2174\/0929867327666200810135039","volume":"28","author":"CM Brackett","year":"2021","unstructured":"Brackett CM, Blagg BSJ. Current status of sumoylation inhibitors. Curr Med Chem. 2021;28:3892\u2013912. https:\/\/doi.org\/10.2174\/0929867327666200810135039.","journal-title":"Curr Med Chem"},{"key":"6271_CR121","doi-asserted-by":"publisher","first-page":"58995","DOI":"10.18632\/oncotarget.10636","volume":"7","author":"J Wu","year":"2016","unstructured":"Wu J, et al. Momordin Ic, a new natural SENP1 inhibitor, inhibits prostate cancer cell proliferation. Oncotarget. 2016;7:58995\u20139005. https:\/\/doi.org\/10.18632\/oncotarget.10636.","journal-title":"Oncotarget"},{"key":"6271_CR122","doi-asserted-by":"publisher","first-page":"e37693","DOI":"10.1371\/journal.pone.0037693","volume":"7","author":"W Huang","year":"2012","unstructured":"Huang W, et al. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS ONE. 2012;7:e37693. https:\/\/doi.org\/10.1371\/journal.pone.0037693.","journal-title":"PLoS ONE"},{"key":"6271_CR123","doi-asserted-by":"publisher","first-page":"eabh1486","DOI":"10.1126\/scitranslmed.abh1486","volume":"13","author":"AC Bellail","year":"2021","unstructured":"Bellail AC, et al. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors. Sci Transl Med. 2021;13:eabh1486. https:\/\/doi.org\/10.1126\/scitranslmed.abh1486.","journal-title":"Sci Transl Med"},{"key":"6271_CR124","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nchembio.2007","volume":"12","author":"JI Stuckey","year":"2016","unstructured":"Stuckey JI, et al. A cellular chemical probe targeting the chromodomains of polycomb repressive complex 1. Nat Chem Biol. 2016;12:180\u20137. https:\/\/doi.org\/10.1038\/nchembio.2007.","journal-title":"Nat Chem Biol"},{"key":"6271_CR125","doi-asserted-by":"publisher","unstructured":"Sun JX, et al. The Prognosis-Predictive and immunoregulatory role of sumoylation related genes: potential novel targets in prostate Cancer treatment. Int J Mol Sci. 2023; 24. https:\/\/doi.org\/10.3390\/ijms241713603.","DOI":"10.3390\/ijms241713603"},{"key":"6271_CR126","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1038\/s41419-020-2587-9","volume":"11","author":"JC Tseng","year":"2020","unstructured":"Tseng JC, et al. ROR2 suppresses metastasis of prostate cancer via regulation of miR-199a-5p-PIAS3-AKT2 signaling axis. Cell Death Dis. 2020;11:376. https:\/\/doi.org\/10.1038\/s41419-020-2587-9.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06271-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06271-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:39:09Z","timestamp":1741311549000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06271-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6271"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06271-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"286"}}